Abstract
Background: Approximately 50% of patients with colorectal cancer (CRC) develop metastatic lesions. For patients with CRC metastases confined to the liver, hepatic resection provides the best chance of long-term survival and in some cases even cure. However, approximately 85% of patients with metastatic (m)CRC present with liver disease that is initially unresectable. First-line chemotherapy can render such lesions resectable in certain patients. The aim of this review was to evaluate the data from published studies to assess whether in patients with KRAS wild-type tumors, the addition of the EGFR antibody cetuximab to first-line chemotherapy increased the conversion rate of liver-limited metastatic disease from initially unresectable to resectable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
